GE’s ultrasound unit shows 25% growth
The ultrasound business of GE Medical Systems was singled outfor praise last week in GE's announcement of fiscal 1996 financialresults. The Fairfield, CT, conglomerate said that new productsdrove the ultrasound business to grow 25% in a relatively
The ultrasound business of GE Medical Systems was singled outfor praise last week in GE's announcement of fiscal 1996 financialresults. The Fairfield, CT, conglomerate said that new productsdrove the ultrasound business to grow 25% in a relatively flatoverall market.
GEMS's ultrasound unit last year introduced major upgradesfor its Logiq line of scanners, and former GEMS president andCEO John Trani said last month that the upgrades were the keyto a successful year for the business (SCAN 1/8/97). Overall,GEMS was one of five GE businesses that reported double-digitincreases in operating profit.
For the year, GE reported record revenues of $79.2 billion,up 13% compared with $70 billion in 1995. Earnings also set arecord, with the company posting net income of $7.3 billion, up11% compared with $6.6 billion in 1995. The results may make GEthe most profitable company in the U.S. for the year.
GE did not break out sales and earnings figures for GE MedicalSystems, other than to report on the growth in ultrasound andoperating profit. GEMS in the past has reported sales of over$3.5 billion.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
